Doomed Dendreon? Many Speculators Shocked By Poor Sales Again
10:01 EDT 2 Aug 2012 | Thomson Reuters
This article has expired, however you can still
download the PDF.
Preview:
By Brian Wilson, ContributorDendreon (DNDN) has been a disastrous holding for many investors who may have been initially optimistic about the company's drug PROVENGE. I initiated coverage on the distressed biotech name on July 21st of this year with ...
Other Sources for this Article
More From BioPortfolio on "Doomed Dendreon? Many Speculators Shocked By Poor Sales Again"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
